At GSK, Stout departs, Viehbacher stays

GlaxoSmithKline President of Pharmaceuticals David Stout is leaving Feb. 29, 2008. Stout was considered to replace J.P. Garnier when he retires as CEO next May, but was passed over in favor of Andrew Witty (1"The Pink Sheet" Oct. 15, 2007, p. 3). President of U.S. Pharmaceuticals Chris Viehbacher, who also vied for the top spot, will join the company's board of directors Jan. 31, along with Witty. There are no plans to replace Stout, GSK tells "The Pink Sheet." Instead, those reporting to Stout will report directly to Witty, beginning Jan. 31. The company made offers to retain both Stout and Viehbacher...